Overview: SALL4 TestIntroduction: The SALL4 Test detects SALL4 expression to diagnose germ cell tumors, causing lumps or weight loss. Aligned with 2023 ASCO guidelines, it uses immunoassays for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected germ cell tumors like seminoma or teratoma.
Other Names: SALL4 Assay, Germ Cell Tumor Marker Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: SALL4 testing began in the 2000s with germ cell tumor research. Immunoassay methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Detects SALL4 expression to diagnose germ cell tumors, guides treatment, and evaluates patients with lumps or weight loss.
Test Parameters: 1. SALL4 Expression
Pretest Condition: No fasting required. Collect serum or plasma. Report history of lumps, weight loss, or cancer symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document lumps, weight loss, or history of germ cell tumors. Include current medications, especially chemotherapy agents.
Consent: Written consent required, detailing the tests purpose, germ cell tumor implications, and risks of sample collection.
Procedural Considerations: Uses enzyme-linked immunosorbent assay (ELISA) to detect SALL4 expression. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for germ cell tumor diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Non-germ cell tumors may cause false negatives.
Clinical Significance: Positive SALL4 expression confirms germ cell tumors, guiding chemotherapy or surgery. Negative results may require tumor marker panels.
Specialist Consultation: Consult an oncologist for result interpretation and treatment planning.
Additional Supporting Tests: AFP, hCG, or tumor biopsy to confirm germ cell tumor diagnosis.
Test Limitations: Non-specific for certain tumor types; clinical correlation is needed. Sample quality affects sensitivity.
References: ASCO Germ Cell Tumor Guidelines, 2023; Journal of Clinical Oncology, Cao D, 2022.
